Martin Dietrich, Medical Oncologist at The US Oncology Network, shared on X:
“Daraxonrasib has been added to NCCN guidelines for KRASmt non-small cell lung cancer. Dose at 200 mg instead of 300 . Great speed, many patients that will benefit from this swift inclusion.”
This also can be interesting:
